Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Septerna, Inc. ( (SEPN) ).
On April 13, 2026, Septerna, Inc. reported that it has begun dosing participants in a Phase 1 clinical trial of SEP-479, an oral small molecule parathyroid hormone 1 receptor agonist being developed to treat hypoparathyroidism. The program targets a disease currently managed with frequent calcium and vitamin D dosing or daily PTH injections, aiming to offer a more convenient therapy for patients.
The randomized, placebo-controlled study in up to 150 healthy adults includes single- and multiple-ascending dose cohorts to assess safety, tolerability, pharmacokinetics and pharmacodynamics, with dosing already underway in the single-dose arm. Septerna expects initial data readouts in late 2026 or early 2027, a milestone that could advance its position in endocrine drug development if SEP-479 demonstrates a favorable risk-benefit profile.
The most recent analyst rating on (SEPN) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Septerna, Inc. stock, see the SEPN Stock Forecast page.
Spark’s Take on SEPN Stock
According to Spark, TipRanks’ AI Analyst, SEPN is a Neutral.
The score is driven primarily by improving financial direction (notably strong 2025 cash flow and revenue growth) but constrained by continued large net losses and volatility. Technicals remain soft with bearish momentum, while valuation is limited by negative earnings. Recent corporate updates are a meaningful positive offset due to favorable Phase 1 results and pipeline advancement plans.
To see Spark’s full report on SEPN stock, click here.
More about Septerna, Inc.
Septerna, Inc. is a clinical-stage biotechnology company focused on advancing G protein-coupled receptor drug discovery using its proprietary Native Complex Platform to develop novel oral small molecule therapies. The South San Francisco-based firm is building a diversified pipeline across endocrinology, immunology and inflammation, metabolic diseases and other areas targeting patients with significant unmet medical needs.
The company leverages a team of GPCR experts and drug developers to unlock new treatment modalities in these indications. Its strategy combines internal programs with partnered efforts to broaden the reach of its technology and position Septerna competitively in emerging GPCR-targeted therapeutics markets.
Average Trading Volume: 289,157
Technical Sentiment Signal: Buy
Current Market Cap: $1.04B
For an in-depth examination of SEPN stock, go to TipRanks’ Overview page.